E
Ennova Pharmaceuticals
Informatics-guided Innovative Medicine Discovery
About Ennova Pharmaceuticals
Ennova Pharmaceuticals, legally registered as Shanghai Yinno Pharmaceutical Co., Ltd., is a clinical-stage drug discovery company established in Shanghai's Zhangjiang Hi-Tech Park in December 2016. The company was co-founded by Dr. Lei Jiang, who serves as CEO, and Dr. Jianyong Shou, the Chief Scientific Officer (CSO). Both founders possess extensive experience from working in major multinational pharmaceutical corporations. Dr. Jiang received his Ph.D. from the University of Wisconsin-Madison and was a senior investigator at Novartis, while Dr. Shou held significant roles at Novartis, GlaxoSmithKline, and Eli Lilly, contributing to multiple new drug R&D projects.
The firm concentrates on the research and development of first-in-class drugs, particularly targeting immunology and metabolic complications. Ennova aims to address unmet medical needs, with a specific focus on diseases that are prevalent in China. Its business model is centered on internal discovery and development, supplemented by strategic external partnerships to enhance its pipeline and capabilities. The company leverages its proprietary eSTEM systems biology platform, along with expertise in medicinal chemistry and computer-aided drug design, to guide its research. This informatics-guided approach is applied across the R&D process to identify and validate novel drug targets.
Ennova's primary therapeutic areas are autoimmune diseases, chronic inflammatory conditions, and metabolic complications such as diabetic retinal diseases. For autoimmune and inflammatory diseases, the company develops novel inhibitors that target key regulatory nodes in the immune system. In the area of metabolic diseases, it focuses on creating small molecule drugs for oral administration to treat conditions driven by metabolic dysregulation, oxidative stress, and inflammation. Ennova has successfully raised capital through multiple funding rounds, including a Series A in November 2019 and a Series B in September 2021, backed by investors like Sailing Capital, Shanghai Healthcare Capital, and Yingke Capital. The company has also entered into collaborations, such as a partnership with D&A Bio-pharmaceuticals to co-develop siRNA drugs for liver diseases.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- Huangpu, China
- Sector
- Biotech & Life Sciences
News
Open roles
Ennova Pharmaceuticals in the Huangpu ecosystem
The Ennova Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Highlight Capital
Series A2 investors entered at this stage
Matrix Partners China
Sunland fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ennova Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ennova Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

